IMC Chicago
BBIO icon

IMC Chicago’s BridgeBio Pharma BBIO Stock Holding History

IMC Chicago’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-19,106
Closed -$932K – 3605
2025
Q2 		$825K Buy
+19,106
New +$695K ﹤0.01% 2594

Other funds holding BBIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

IMC Chicago's BBIO Position: Q3 2025 in Review

IMC Chicago sold out of BridgeBio Pharma (BBIO) in Q3 2025, closing a stake of 19,106 shares — an estimated $932K sold.

IMC Chicago first reported a position in BBIO in Q2 2025 and held it in 1 quarter. The position peaked at $825K in Q2 2025. 392 funds tracked by Wall St. Rank hold BBIO as of Q3 2025.

  • IMC Chicago reported no remaining BridgeBio Pharma position as of Q3 2025 after selling out during the quarter.
  • IMC Chicago sold 19,106 BridgeBio Pharma shares in Q3 2025, an estimated $932K.
  • IMC Chicago first reported a position in BridgeBio Pharma in Q2 2025 and held it in 1 quarter.
  • IMC Chicago's BridgeBio Pharma position peaked at $825K in Q2 2025.
  • 392 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2025.

Based on IMC Chicago's 13F filing for Q3 2025, filed 4 Nov 2025.